Analysts have set 12-month price targets for Alkermes, revealing an average target of $38.0, a high estimate of $50.00, and a ...

The market expects Alkermes (ALKS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is ...

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and ...

Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report) and Ocular ...

Six fast-growing startups have been selected to receive a $100,000 investment each and will participate in the 12-week ...

Alkermes Plc (ALKS) is up more than +1% after it said its ALKS 2680 demonstrated clinically meaningful and statistically ...

Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.

Business & Finance has released the annual Leading in Wellbeing Index, recognising the wellness leaders operating in Ireland ...

(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor and industry conferences during the month of May: ...

Growing need for effective delivery of novel biopharmaceuticals and pharmaceutical coupled with innovation in drug delivery ...

Major market player included in this report are: Alkermes plc (Ireland) Allergan, Inc. (Ireland) GlaxoSmithKline plc (UK) Mylan N.V.(US) The objective of the study is to define market sizes of ...